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Abstract
Background Despite a fast and potent growth of the future liver remnant (FLR), patients operated with associating liver partition
and portal vein ligation for staged hepatectomy (ALPPS) are at risk of developing posthepatectomy liver failure. In this study, the
relation between liver volume and function in ALPPS was studied using a multimodal assessment.
Methods Nine patients with colorectal liver metastases treated with neoadjuvant chemotherapy and operated with ALPPS were
studied with hepatobiliary scintigraphy, computed tomography, indocyanine green clearance test, and serum liver function tests.
A comparison between liver volume and function was conducted.
Results The preoperative FLR volume of 19.5% underestimated the preoperative FLR function of 25.3% (p = 0.011). The increase in
FLR volume exceeded the increase in function at day 6 after stage 1 (FLR volume increase 56.7% versus FLR function increase
28.2%, p = 0.021), meaning that the increase in function was 50% of the increase in volume. After stage 2, functional increase
exceeded the volume increase, resulting in similar values 28 days after stage 2.
Conclusions In the inter-stage period of ALPPS, the high volume increase is not paralleled by a corresponding functional increase.
This may in part explain the highmorbidity andmortality rates associated with ALPPS. Functional assessment of the FLR is advised.
Keywords Colorectal cancer . Liver metastases . Liver
function tests . ALPPS
Introduction
Indications for liver resection in colorectal liver metastases
(CRLM) have changed over the last two decades, from the
historical tumor-based criteria to the current paradigm where the
focus is on the future liver remnant (FLR).1, 2 With the current
widely accepted definition of resectability, resection is indicated
when R0 resection of metastases, including extrahepatic disease,
can be achievedwhile preserving a FLR sufficient formaintaining
postoperative function and allowing adequate regeneration to re-
storesustainableliverfunction.3Thereisincreasedfocusonextend-
ing potential curative surgery to patients currently not eligible for
treatment.Conversionstrategiescanbedividedintotumor-directed
treatments (multi-modality local tumor therapyandchemotherapy)
or enhancement of postoperativehepatic functional reservebyma-
nipulation of the FLR.4 Portal vein occlusion (PVO), by either
portal vein embolization (PVE) or portal vein ligation (PVL), is a
well-establishedtechniquefor inducinghypertrophyof theFLR.5, 6
Inarecentlypublishedmeta-analysis, the twotechniques(PVEand
PVL)were found tobecomparable in termsofgrowth inducedand
operativemorbidity andmortality.7Diseaseprogressionduring the
longwaitingtimesleadingtounresectablesituationshasbeenraised
as a concern.5, 8–10
Associating liver partition and portal vein ligation for
staged hepatectomy (ALPPS) is a novel two-stage technique
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intended to induce rapid growth of the FLR.11 Increase in FLR
ranging from 65 to 110% and interval between the stage 1 and
2 procedures ranging from 6 to 15 days have been reported.12
Conceptually, ALPPS is potentially more versatile in its ap-
plication. For example, the FLR is not confined to the classic
sector-restricted FLR and a number of configurations with a
single segment as FLR (so-called mono-segment ALPPS)
have been described.13 Concern has been voiced that the ex-
treme increase in size is the result of trauma-induced edema
and swelling due to excessive portal flow, rather than a true
hypertrophy.14 Furthermore, it is unclear whether the increase
in volume due to hypertrophy translates into a comparable
increase in function. Hepatobiliary scintigraphy (HBS) studies
have shown that the increase in FLR function after PVE pre-
cede and is more pronounced than the increase in FLR
volume.15 Recently, a case report and one preliminary report
using HBS in ALPPS have suggested a discrepancy between
liver volume and function, in that FLR volume instead over-
estimates FLR function after the stage 1 operation in
ALPPS.16, 17
In this study, we investigate the dynamics of volume and
function change in the FLR in patients operated with the
ALPPS procedure after both stages of the operation, to ex-
plore whether increase in volume is translated into a corre-
sponding increase in function.
Materials and Methods
Patients
In Stockholm County, all patients with colorectal liver metas-
tases considered for intervention are discussed at a regional
hepatobiliary multidisciplinary team conference for assess-
ment and treatment planning. Patients with CRLM and re-
sponse to neoadjuvant chemotherapy that could be rendered
tumor free by an extended right-sided hemihepatectomy (seg-
ments IV-VIII), with or without local resection or ablation in
the FLR, but where the FLR was insufficient (i.e., a future
liver remnant to body weight—FLR/BW—of less than
0.5%) were eligible for the study. This was a prospective ob-
servational study that included an extensive repeated multi-
modal liver volume and function evaluation of each patient.
Patients were included after obtaining informed consent. The
nature and timing of study-related investigations are summa-
rized in Table 1.
Operative Intervention and Postoperative Assessment
After mobilization of the right liver and cholecystectomy, the
right portal vein was identified and divided using a surgical
stapler (Endo GIA™ Universal with Tri-Staple™, Covidien,
Dublin, Ireland). The right hepatic vein and pedicle containing
the right hepatic artery and right bile duct were isolated and
circled with rubber vessel loops. Any tumors in the FLR were
resected or microwave ablated, and complete parenchymal
transection to the inferior vena cava was performed immedi-
ately to the right of the falciform ligament using a cavitron
ultrasonic surgical aspirator (CUSA®, Valleylab Inc, Boulder,
CO, USA). The deportalized liver was wrapped in a plastic
bag, a surgical drain was placed in the crevice created by the
parenchymal division, and the abdomen was closed. If
volumetry performed on the four-phase contrast enhanced
computed tomography (CE-CT) on the sixth postoperative
day showed sufficient hypertrophy of the FLR (resulting in a
FLR/BW >0.5%), the stage 2 procedure was performed on
day 7. At the stage 2 operation, the right pedicle (right hepatic
artery and bile duct) and right hepatic vein were divided using
surgical stapler and the deportalized liver was removed. The
abdomen was closed retaining the surgical drain that was
placed at the first operation.
Indocyanine Green Clearance and Serum Liver Function
Tests
Indocyanine green clearance (ICG-C) measured as plasma
retention at 15 min, expressed as percentage (ICG-R15%),
was performed using the LiMON® system (PULSION
Medical System, Munich, Germany) after intravenous injec-
tion of 0.5 mg/kg of ICG dye (Verdye®, Diagnostic Green
GmbH, Aschheim-Dornach, Germany). Prothrombin time
measured as the international normalized ratio (INR) and se-
rum bilirubin levels were measured daily from the day before
stage 1 until day 7 after stage 2 and then again on day 28 after
stage 2.
CT Volumetry
For calculation of the total estimated liver volume (TELV), the
standardized formula as proposed by Vauthey et al. was
used.18 The FLR volume was measured on the preoperative
day and day 6 after stage 1 on CE-CT and on days 7 and 28
Table 1 Timing of study-related investigations
Time 4-phase CE-CT HBS with SPECT/CT ICG-C
Day 1 pre-stage 1 X X X
Day 1 post-stage 1 – – X
Day 6 post-stage 1 X X X
Day 1 post-stage 2 – – X
Day 7 post-stage 2 – X X
Day 28 post-stage 2 – X X
CE-CT contrast enhanced computed tomography, HBS with SPECT/CT
hepatobiliary scintigraphy with SPECT/CT, ICG-C indocyanine green
clearance test
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after stage 2 on the CT from the SPECT/CT. The standardized
FLR (sFLR) was calculated by dividing the FLR with TELV,
and percentage FLR increase on day 6 after stage 1 and days 7
and 28 after stage 2 examinations was calculated with the
preoperative TELV and preoperative FLR volume as refer-
ences. The kinetic growth rate of the FLR volume was calcu-
lated separately for the three time intervals (between the stage
1 and 2 operations, for the first 7 days after stage 2 and for
days 8–28 after stage 2) expressed as percentage change per
day. All liver volume calculations were performed using
Volume Viewer© (Voxtool 11) for AW Volume Share 5 im-
plemented on an AW Workstation (GE Healthcare, Fairfield,
CT, USA).
Scintigraphy
HBS and calculation of functional parameters were performed
according to a method described previously.19, 20 Imaging was
performed in the supine position using a large-field-of-view
SPECT/CT camera (Symbia T-16, Siemens, Erlangen,
Germany), equipped with low-energy high-resolution colli-
mators, positioned over the liver and heart. Hepatic uptake
function was calculated from dynamic acquisitions (36 frames
of 10 s/frame, 128 matrix) performed directly after intrave-
nous administration of 200 MBq 99mTc-labeled (2,4,6
trimethyl-3-bromo) iminodiacetic acid (99mTc-mebrofenin,
Bridatec®, GE Healthcare, Milan, Italy). For three-
dimensional assessment of liver function and calculation of
functional liver volumes, the dynamic acquisition was
followed by a fast SPECT acquisition (60 projections of 8 s/
projection, 128 matrix) centered around the peak of the hepat-
ic time-activity curve. Without repositioning the patient, a
low-dose non-contrast-enhanced CTwas performed for atten-
uation correction and anatomical mapping. Data were proc-
essed on a Hermes workstation (Hermes Medical Solutions
AB, Stockholm, Sweden). An example of HBS with
SPECT/CTat the four time points in a patient with insufficient
growth after previous PVE is shown in Fig. 1.
Calculations of Scintigraphic Functional Parameters
Planar Dynamic
Total liver 99mTc-mebrofenin uptake rate (%/min),
representing total liver function, was calculated from the dy-
namic acquisitions as geometric mean (Gmean = square root
of the multiplication of anterior and posterior data sets) using
the intensity values acquired 150 to 350 s after isotope injec-
tion from regions of interest (ROI) over the liver, the medias-
tinal blood pool (heart and large vessels), and the total field of
view. To compensate for differences in individual metabolic
requirements, total liver function was divided by body surface
area according to the Mosteller formula and expressed as
%/min/m2. For calculation of the FLR function, a ROI delin-
eating the FLR was drawn. On the preoperative examination,
the falciform ligament/umbilical fissure, as visible on anterior
CT projections, was used to delineate the border between seg-
ments II/III and IV. On day 6 after stage 1 examination, the
Fig. 1 HBS with SPECT/CT in a
patient with insufficient growth
after previous PVE before stage 1
(a), on day 6 after stage 1 (b), day
7 (c), and day 28 (d) after stage 2
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FLRwas well demarcated by the crevice between segments II/
III and segment IV facilitating drawing of ROIs in the FLR as
well as the deportalized liver for calculation of deportalized
liver function. Calculation of FLR function and deportalized
liver function was done by dividing the added counts 150–
350 s after isotope injection within the respective delineated
ROIs by the total liver counts within the same time frame and
multiplying this factor by the total liver 99mTc-mebrofenin
uptake rate with values expressed as %/min/m2. Mebrofenin
uptake per liter of FLR tissue was calculated by dividing the
FLR function (not corrected for body surface area) by FLR
volume and expressed as %/min/l. Increase in FLR function
on day 6 after stage 1 and on day 7 and day 28 after stage 2
was calculated with the preoperative FLR function as refer-
ence and expressed as percentage increase. Kinetic growth
rate in FLR function was calculated for the three time intervals
(between the stage 1 and 2 operations, during the first seven
and days 8–28 after stage 2) by dividing the percentage in-
crease for each time period with the number of elapsed days
and expressed as percentage increase per day.
SPECT
For three-dimensional assessment of liver function, the liver
was automatically delineated on the SPECT images by an
outline extraction method (with a threshold of 30% of the
maximal voxel count value). Activity within the bile ducts
was eliminated bymanual subtraction of extrahepatic bile duct
activity and replacement of intrahepatic bile duct activity by
an average density count of normal liver tissue. The FLR and
deportalized liver (preoperatively the Bto be deportalized
liver^) were outlinedmanually on the SPECT/CT images with
the CE-CT images used as reference. Total liver functional
volume and FLR functional volume were subsequently calcu-
lated using the same threshold. The volume of the Bto be
deportalized liver functional volume^ on the preoperative ex-
amination was estimated by subtracting the preoperative FLR
functional volume from the preoperative total liver functional
volume, whereas an actual calculation was performed for the
day 6 deportalized liver functional volume, where the
deportalized liver could clearly be delineated on the divided
liver. The preoperative total liver functional volume was used
as reference for calculation of both the preoperative and day 6
deportalized liver functional volume/total liver functional vol-
ume ratios.
Data Collection and Statistical Analysis
Baseline patient characteristics, volumetric data, procedural
data, and complications were collected prospectively in a local
database. Median values with range or inter-quartile range
were used for continuous variables whereas frequencies were
calculated for categorical variables. The Wilcoxon signed-
rank test was used to compare differences in liver volume
and function, and the Spearman’s rank correlation coefficient
was used to test for correlation between volumetric and func-
tional parameters. Two-tailed p values of <0.05 were consid-
ered to represent statistical significance. Statistical analysis
was performed using SPSS® Statistics, version 23 (IBM,
Chicago, IL, USA) and GraphPad Prism®, version 7
(GraphPad Software, La Jolla, CA, USA).
The study was approved by the Regional Ethical Review
Board (approval number 2013/353-31/1) and the Radiation




Between November 2012 and March 2014, nine patients with
CRLM were included in the study. All patients received neo-
adjuvant chemotherapy consisting of FOLFOX or FOLFIRI
with addition of a biological agent in two patients. A median
of six cycles (range 4–14) of chemotherapy were given. All
patients had response to this treatment according to RECIST
criteria.21 In five patients, the liver metastases were detected
synchronous to the primary tumor and two patients had tumor
in the FLR. Six patients had previous failed PVO (PVE 3;
PVL 2; PVL; and PVE 1) prior to inclusion, meaning that
PVO did not induce sufficient growth of the FLR with a
FLR/BW still below 0.5% after evaluation of the PVO effect.
The stage 2 operation was performed in all patients 7 days
after the stage 1 operation. Patient characteristics are summa-
rized in Table 2.
Clinical Outcome
Themedian operating time for stage 1 was 280min (range 200–
498) and for stage two 47 min (29–107). Median intraoperative
bleeding was 1500 ml (range 400–5600) for stage 1 and 150 ml
(50–700) for stage 2. Two patients required tumor clearance in
the FLR performed at the stage 1 operation, consisting of a local
resection in segment 3 in one patient and a microwave ablation
deep in the left lateral sector in the other. All patients completed
the stage 2 operation with removal of segments IV-VIII.
Pathological examination showed radical resection (R0) in sev-
en patients while two patients had tumor cells within 1mm from
the resection line (R1). One patient with bile leakage after stage
2 required endoscopic stenting under general anesthesia, thus
denoted as a grade 3b-complication according to the Clavien-
Dindo classification.22 Three patients had pleural effusions re-
quiring drainage under local anesthetic (grade 3a complication).
No patient developed severe posthepatectomy liver failure and
there was no 90-day mortality.
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Indocyanine Green Clearance and Serum Liver Function
Tests
The median ICG-R15 on the day before stage 1 operation was
9.9% (range 1.2–20.7) and on day 6 after stage one 7.0% (4.2–
19.5). There was a significant rise in ICG-R15 directly after
stage 2 (33.3%, 8.5–43.2, p = 0.012) that was maintained at
day 7 after stage 2 (28.8%, 19.2–38.9) and at day 28 after
stage 2 (22.2%, 10.3–37.5). A graphical presentation of the
ICG dynamics in ALPPS is shown in Fig. 2.
Median INR and bilirubin levels prior to the stage 1 oper-
ation were 1.0 (range 1.0–1.3) and 6 μmol/l (4–8), respective-
ly. On day 5 after stage 1, median INR was elevated to 1.3
(range 1.1–1.5, p = 0.007) and bilirubin to 10 (7–22, p =
0.020), without any patients fulfilling the criteria for severe
posthepatectomy liver failure according to the three most
commonly used definitions.23–25 On day 5 after stage 2, both
INR and bilirubin continued to rise with a median INR of 1.5
(range 1.2–1.8, p = 0.011) and bilirubin of 21 (12–49, p =
0.028), still without any patient developing severe
posthepatectomy liver failure. There was a negative correla-
tion between ICG-R15 levels at day 7 after stage 2 and the
inter-stage increase in FLR volume (Spearman’s Rho = −0.68,
p = 0.045), meaning that a high ICG-R15 level correlated with
a lower increase in FLR volume.
CT Volumetry
The median preoperative FLR volume was 300 ml (range 260–
433) translating into a median sFLR of 19.5% (16.1–25.8). On
day 6 after stage 1 and days 7 and 28 after stage 2, the FLR
volume had increased to 557, 700, and 793 ml, respectively
(p = 0.008, 0.011, and 0.008), translating into a median sFLR
of 33.1, 40.6, and 48.0%. The median FLR volume percentage
increase on day 6 after stage 1, day 7 and day 28 after stage 2
were 56.7% (range 32.3–110.4), 114.7% (48.8–174.3), and
132% (90–218.3) using the preoperative FLR volume and
TELV as references. Median FLR/BW before stage 1 was
0.41% (range 0.35–0.49) and increased to 0.71% (0.54–0.90,
p = 0.008) prior to stage 2. Themedian kinetic growth rate of the
FLR volume was 9.4%/day (range 5.4–18.4) in the 6 days be-
tween stage 1 and 2, 3.8%/day (−0.3–8.2) the first 7 days after
stage 2, and 0.5%/day (0.1–4.2) from day 8 to 28 after stage 2.
The relation between increase in FLR volume and the kinetic
growth rate of the FLR volume is demonstrated in Fig. 3a.
Scintigraphic Functional Analysis
Planar Dynamic Parameters
The median preoperative FLR function was 1.8%/min/m2
(range 1.4–2.9), translating into a median FLR function/total
Table 2 Patient characteristics before ALPPS
Variable Patients (n = 9)
Median age, years 69 (41–77)
Male/female gender 6/3




Median number of liver metastases 4 (1–12)
Tumor localization
Right lobe + segment 4 7





Number of chemotherapy cycles 6 (4–14)
Portal vein occlusion prior to ALPPS
No portal vein occlusion 3
Portal vein embolization (PVE) 3
Portal vein ligation (PVL) 2
First PVL then PVE 1
FLR before PVO (ml) 219 (140–306)
sFLR before PVO (%) 13.6 (9.3–18.2)
FLR/BW before PVO (%) 0.30 (0.19–0.38)
FLR before ALPPS (ml) 300 (260–433)
sFLR before ALPPS (%) 19.5 (16.1–25.8)
FLR/BW before ALPPS (%) 0.41 (0.35–0.49)
Continuous variables are expressed as median with range in parentheses
ASAAmerican society of anesthesiologists physical classification system,
TELV total estimated liver volume, FLR future liver remnant, sFLR stan-
dardized FLR, FLR/BW FLR to body weight ratio
Fig. 2 Indocyanine green retention at 15 min (ICG-R15%) at six time
points before and after both stages of the ALPPS procedure. Data are
presented as median with inter-quartile range. *p < 0.05, **p < 0.01
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liver function share of 25.3% (19.3–33.1). On day 6 after stage
1 and days 7 and 28 after stage 2, the median FLR function
had increased to 2.6, 3.4, and 4.1%/min/m2, respectively
(p = 0.051, 0.036, and 0.011), resulting in FLR function/total
liver function shares of 33.9, 43.7, and 55.5%. Using the pre-
operative FLR function and total liver function share as refer-
ence, the median FLR function increase on day 6 after stage 1,
day 7, and day 28 after stage 2 were 28.2% (range −35.7–
83.8), 66.4% (0.7–147.5), and 92.2% (47.3–191.5), respec-
tively. It was notable that the median FLR uptake rate per
volume unit was decreased significantly on day 6 after stage
1 (8.5%/min/l) compared to preoperatively (11.8%/min/l,
p = 0.028), and did not surpass the preoperative values on
day 7 (9.0%/min/l) or on day 28 after stage 2 (10.1%/min/l).
The median kinetic growth rate of the FLR function was
4.7%/day (range −6–14) in the 6 days between stage 1 and
2. During the 7 days following stage 2, it was 4.9%/day (range
−2–24.9) and from day 8 to 28 after stage two 1.4%/day
(−0.3–2.2). The relation between increase in FLR function
and the kinetic growth rate of FLR function is demonstrated
in Fig. 3b.
SPECT Parameters
An increase in the total liver functional volume (median
values 1322 and 1637 ml, p = 0.008) was seen on day 6 after
stage 1 whereas the Bto be deportalized liver functional
volume^ and deportalized liver functional volume (941 and
1014 ml) did not increase significantly. A slight decrease in
the deportalized liver function was seen prior to stage 2 as
compared to the Bto be deportalized liver function^ prior to
stage 1 (7.0%/min/m2 and 8.3%/min/m2), but it did not reach
statistical significance (p = 0.208). There was no correlation
between the increase in FLR function and decrease in
deportalized liver function prior to stage 2 (Spearman’s
Rho = −0.42, p = 0.265).
Volume Versus Function
ThepreoperativesFLRof19.5%underestimatedthepreoperative
FLR function/total liver function share of 25.3%(p = 0.011).The
median increase in volume exceeded the increase in function at
day 6 after stage 1 (FLR volume increase 56.7% versus FLR
function increase 28.2%, p = 0.021). The increase in volume still
exceeded increase in function the first 7 days after stage 2 (FLR
volume increase 114.7% versus FLR function increase 66.4%,
p = 0.028) but with greater functional growth rate after stage 2
resulted in comparable levels on day 28 (FLR volume increase
132.0% versus FLR function increase 92.2%, p = 0.11), with the
preoperative FLR volume and FLR function as reference. The
perioperative relation between FLR volume and FLR function
increase is also demonstrated in Fig. 4.
The median kinetic growth rate for FLR volume and FLR
function between the stage 1 and 2 operations, during the first
7 days after stage 2 and days 8–28 after stage 2 measured on
CT volumetry and planar dynamic scintigraphy, is shown in
Fig. 5.
Fig. 3 a FLR volume (FLR-V in ml) compared to kinetic growth rate
(KGR) of volume increase (%/day) at the four time points: pre-stage 1,
day 6 after stage 1, day 7 and 28 after stage 2. b FLR function (FLR-F as
%/min/m2) compared to KGR of function increase (%/day) at the four
time points: pre-stage 1, day 6 after stage 1, day 7 and 28 after stage 2.
Data are presented as median with inter-quartile range
Fig. 4 Comparison of percentage increase in FLR volume (FLR-V) and
function (FLR-F) day 6 after stage 1 and days 7 and 28 after stage 2, with
preoperative FLR-V and FLR-F as reference. Data are presented as me-
dian with range. ns not significant
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Discussion
The ALPPS procedure has been suggested as an alternative to
PVO for inducing hypertrophy of the FLR.11 Proponents
claim a quicker increase in FLR in a shorter time as compared
to conventional methods for FLR manipulation.12 Resection
rates for patients with CRLM after ALPPS of 97–100% have
been reported, compared to around 70–80% after PVO.12
Tumor recurrence rates at 1-year follow-up for ALPPS and
PVO were comparable.26 As mentioned previously, skeptics
have raised concern that the extreme increase in FLR size is
not necessarily the result of true hypertrophy.14 Furthermore,
the relationship between hypertrophy and increased function
has been questioned.15–17 Also of concern is the safety of the
ALPPS procedure, with 90-day mortality rates of 15% having
been reported, compared to 6% for surgery after PVO.26
Of the nine patients included in this case series, six had failed
PVO before inclusion. In spite of that, the median increase of
56.7% in FLR volume in only 6 days exceeded the growth that
can be expected after PVO (mean increase of 39% after a mean
of 45 days for PVE; mean increase of 27% after a mean of
59 days for PVL).7 Interestingly though, the kinetic growth rate
for volume exceeded the kinetic increase in function, measured
as percentage increase per day. The 56.7% median increase in
FLR volume was paired with a 28.2% FLR function increase
day 6 after stage 1, or in other words the functional increase
represented only 50% of the increase in volume. This was also
reflected as a decreased FLR uptake rate per volume unit on day
6 (median 8.5%/min/l on day 6 after stage 1 compared to 11.8%/
min/l preoperatively). This gives some legitimacy to fears that
the fast initial growth in volume after ALPPS does not translate
into an equivalent increase in function.14 This may, in part,
explain the observation that extreme hypertrophy does not nec-
essarily ensure a sufficient FLR and safe postoperative course.27
However, a higher kinetic increase in FLR function than FLR
volume after the stage 2 operation results in comparable values
in FLR volume and FLR function on day 28 after stage 2.
In a letter to the editor, Lau et al. presented a case report
suggesting using repeated ICG clearance measurement for
resectability decision-making in ALPPS.28 In the present
study, ICG-R15 values did not increase directly after stage 1
or prior to stage 2. The potent increase in ICG-R15 seen from
day 1 after stage 2 did not translate into liver failure, and might
simply be a result of increased blood flow to the liver remnant
after resecting the deportalized liver. Whether a sharp increase
in ICG-R15 prior to stage 2 could indicate a need to postpone
stage 2 operation remains to be investigated in larger studies.
This study has some limitations. One obvious limitation is the
small number of patients included in the study. This is a common
problemformoststudies in the fieldofPVOandALPPSdue to the
limited number of patients that are subjected to these procedures.
Still, themain findings in the present study are supported by initial
experiences from other recent reports in that the FLR volume
seems to overestimate FLR function after stage 1 of the ALPPS
procedure.16, 17 Another potential confounder is that amajority of
the patients in this study (six out of nine) were subjected to rescue
ALPPS (after failed PVO).One could speculate that the hypertro-
phyof theFLRafterALPPS inapatientwithpreviousPVOmight
be less pronounced compared toALPPS upfront. However, there
iscurrentlynoevidence tosupport thishypothesis. Infact, thereare
indications that the growth of the FLR after rescueALPPS is sim-
ilar toALPPS upfront.29, 30 Finally, several factors are considered
to impair the growth of FLR. Among the most commonly de-
scribed are pre-procedural chemotherapy, high bilirubin levels,
concomitant cholangitis, and diabetesmellitus.31, 32 However, re-
sult fromdifferent studies are conflictingand the evidencegrade is
poor.33ComparedtomanypreviousstudiesinALPPS,thepatients
in this study represent a comparatively homogenous cohort in that
they all received chemotherapy for CRLM only, no patient had
high bilirubin, cholangitis, or diabetes, and theywere all operated
withanextended right-sidedhemihepatectomyon theseventhday
after stage1operation.Still,untilmoresolidevidence ispresented,
interpretationof the results in the present studyhas tobe undertak-
enwith these limitations inmind.
Conclusion
In conclusion, this study supports previous reports indicating that
ALPPS result in superior increases in both volume and function of
the FLR as compared to PVO.However, the dynamics in terms of
growth differ, with the inter-stage increase in volume not being
matchedwith an equivalent increase in function. This discrepancy
is neutralized by amore rapid increase in function after the second
operation.Caution is advised in proceeding to second-stage proce-
dures solely on volume-based assessments, especially when volu-
metric assessment is performed less than a week after the initial
operation. The addition of functional parameters will probably
Fig. 5 Median percentage change per day (KGR) in FLR volume (FLR-
V) and function (FLR-F) between stage 1 and 2 operations, during the
first 7 days after stage 2 and during days 8–28 after stage 2 as measured
on CT volumetry (FLR-V) and planar dynamic scintigraphy (FLR-F).
Data are presented as median with inter-quartile range
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result inmore prudent decision-making and could lowermortality
andmorbidity inpatientssubjectedtothis important,butpotentially
dangerous intervention.
Authors Contributions Study conception and design—ES, BI
Acquisition of data—ES, TB, EJ, RA, BI
Analysis and interpretation of data—ES, EJ, AT, UD, GM
Drafting manuscript—ES
Critical revision of manuscript—EJ, AT, UD, GM, TB, RA, BI
Final approval of the version to be published—ES, EJ, AT, UD, GM,
TB, RA, BI
Agreement to be accountable for all aspects of the work—ES, EJ, AT,
UD, GM, TB, RA, BI
Compliance with Ethical Standards
Conflict of Interest The authors do not have any disclosures to report
and no financial support was received for this study.
Open Access This article is distributed under the terms of the Creative
Commons At t r ibut ion 4 .0 In te rna t ional License (h t tp : / /
creativecommons.org/licenses/by/4.0/), which permits unrestricted use,
distribution, and reproduction in any medium, provided you give appro-
priate credit to the original author(s) and the source, provide a link to the
Creative Commons license, and indicate if changes were made.
References
1. Ekberg, H., et al., Determinants of survival in liver resection for
colorectal secondaries. Br J Surg, 1986. 73(9): p. 727–31.
2. Altendorf-Hofmann, A. and J. Scheele, A critical review of the major
indicators of prognosis after resection of hepatic metastases from co-
lorectal carcinoma.SurgOncol ClinNAm, 2003. 12(1): p. 165–92, xi.
3. Pawlik, T.M., R.D. Schulick, and M.A. Choti, Expanding criteria
for resectability of colorectal liver metastases. Oncologist, 2008.
13(1): p. 51–64.
4. Worni, M., K.N. Shah, and B.M. Clary, Colorectal cancer with
potentially resectable hepatic metastases: optimizing treatment.
Curr Oncol Rep, 2014. 16(10): p. 407.
5. Robles, R., et al., Comparative study of right portal vein ligation
versus embolisation for induction of hypertrophy in two-stage hep-
atectomy for multiple bilateral colorectal liver metastases. Eur J
Surg Oncol, 2012. 38(7): p. 586–93.
6. van Lienden, K.P., et al.,Portal vein embolization before liver resection:
a systematic review.Cardiovasc Intervent Radiol, 2013. 36(1): p. 25–34.
7. Pandanaboyana, S., et al., A systematic review and meta-analysis of
portal vein ligation versus portal vein embolization for elective liver
resection. Surgery, 2015. 157(4): p. 690–8.
8. Aussilhou, B., et al., Right portal vein ligation is as efficient as
portal vein embolization to induce hypertrophy of the left liver
remnant. J Gastrointest Surg, 2008. 12(2): p. 297–303.
9. Broering, D.C., et al., Portal vein embolization vs. portal vein liga-
tion for induction of hypertrophy of the future liver remnant. J
Gastrointest Surg, 2002. 6(6): p. 905–13; discussion 913.
10. Capussotti, L., et al., Portal vein ligation as an efficient method of
increasing the future liver remnant volume in the surgical treatment
of colorectal metastases. Arch Surg, 2008. 143(10): p. 978–82;
discussion 982.
11. Schnitzbauer, A.A., et al., Right portal vein ligation combined with
in situ splitting induces rapid left lateral liver lobe hypertrophy
enabling 2-staged extended right hepatic resection in small-for-
size settings. Ann Surg, 2012. 255(3): p. 405–14.
12. Hasselgren, K., P. Sandstrom, and B. Bjornsson, Role of associating
liver partition and portal vein ligation for staged hepatectomy in
colorectal liver metastases: a review.World J Gastroenterol, 2015.
21(15): p. 4491–8.
13. Schadde, E., et al.,Monosegment ALPPS hepatectomy: extending re-
sectability by rapid hypertrophy. Surgery, 2015. 157(4): p. 676–89.
14. Aloia,T.A.,InsightsintoALPPS.EurJSurgOncol,2015.41(5):p.610–1.
15. de Graaf,W., et al., Increase in future remnant liver function after pre-
operative portal vein embolization.Br J Surg, 2011. 98(6): p. 825–34.
16. Cieslak, K.P., et al., Assessment of Liver Function Using (99m)Tc-
Mebrofenin Hepatobiliary Scintigraphy in ALPPS (Associating
Liver Parti t ion and Portal Vein Ligation for Staged
Hepatectomy). Case Rep Gastroenterol, 2015. 9(3): p. 353–60.
17. Truant, S., et al., Drop of Total Liver Function in the Interstages of
the New Associating Liver Partition and Portal Vein Ligation for
Staged Hepatectomy Technique: Analysis of the BAuxiliary Liver^
by HIDA Scintigraphy. Ann Surg, 2016. 263(3): p. e33-4.
18. Vauthey, J.N., et al., Standardized measurement of the future liver
remnant prior to extended liver resection: methodology and clinical
associations. Surgery, 2000. 127(5): p. 512–9.
19. Ekman, M., et al., Liver uptake function measured by IODIDA
clearance rate in liver transplant patients and healthy volunteers.
Nucl Med Commun, 1996. 17(3): p. 235–42.
20. deGraaf,W., et al., (99m)Tc-mebrofenin hepatobiliary scintigraphywith
SPECT for the assessment of hepatic function and liver functional vol-
ume before partial hepatectomy. J Nucl Med, 2010. 51(2): p. 229–36.
21. Eisenhauer, E.A., et al., New response evaluation criteria in solid
tumours: revised RECIST guideline (version 1.1). Eur J Cancer,
2009. 45(2): p. 228–47.
22. Dindo, D., N. Demartines, and P.-A. Clavien, Classification of
Surgical Complications.Annals of Surgery, 2004. 240(2): p. 205–213.
23. Balzan, S., et al., The B50-50 Criteria^ on Postoperative Day 5: an
accurate predictor of liver failure and death after hepatectomy.
Annals of Surgery, 2005. 242(6): p. 824–829.
24. Mullen, J.T., et al., Hepatic insufficiency and mortality in 1,059
noncirrhotic patients undergoing major hepatectomy. J Am Coll
Surg, 2007. 204(5): p. 854–62; discussion 862–4.
25. Rahbari, N.N., et al., Posthepatectomy liver failure: a definition and
grading by the International Study Group of Liver Surgery (ISGLS).
Surgery, 2011. 149(5): p. 713–24.
26. Schadde, E., et al., ALPPS Offers a Better Chance of Complete
Resection in Patients with Primarily Unresectable Liver Tumors
Compared with Conventional-Staged Hepatectomies: Results of a
Multicenter Analysis. World J Surg, 2014. 38(6): p. 1510–9.
27. Truant, S., et al., Associating liver partition and portal vein ligation
for staged hepatectomy (ALPPS): impact of the inter-stages course
on morbi-mortality and implications for management. Eur J Surg
Oncol, 2015. 41(5): p. 674–82.
28. Lau, L., C. Christophi, and V. Muralidharan, Intraoperative func-
tional liver remnant assessment with indocyanine green clearance:
another toehold for climbing the BALPPS^. Ann Surg, 2015.
261(2): p. e43-5.
29. Tschuor, C., et al., Salvage parenchymal liver transection for pa-
tients with insufficient volume increase after portal vein occlusion—
an extension of the ALPPS approach. Eur J Surg Oncol, 2013.
39(11): p. 1230–5.
30. Ulmer, T.F., et al., ALPPS Procedure in Insufficient Hypertrophy
After Portal Vein Embolization (PVE).World J Surg, 2016.
31. de Baere, T., et al., Predictive factors for hypertrophy of the future
remnant liver after selective portal vein embolization. Ann Surg
Oncol, 2010. 17(8): p. 2081–9.
32. Imamura, H., et al., Preoperative portal vein embolization: an audit
of 84 patients. Hepatology, 1999. 29(4): p. 1099–105.
33. Yokoyama, Y., M. Nagino, and Y. Nimura,Mechanisms of hepatic
regeneration following portal vein embolization and partial hepa-
tectomy: a review. World J Surg, 2007. 31(2): p. 367–74.
J Gastrointest Surg
